UroGen Pharma Q3 2024: Assets $42.2M, Liabilities $32.5M

TL;DR

UroGen Pharma Q3: Assets $42.2M, Liabilities $32.5M. Cash flow positive.

AI Summary

UroGen Pharma Ltd. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $42.2 million and total liabilities of $32.5 million. Cash provided by operating activities was $0.775 million for the nine months ended September 30, 2024.

Why It Matters

This filing provides a snapshot of UroGen Pharma's financial health, indicating its asset base and debt levels as of Q3 2024.

Risk Assessment

Risk Level: medium — The company's financial position shows a significant amount of liabilities relative to assets, and the filing does not provide details on revenue or profitability.

Key Numbers

• $42.2M — Total Assets (As of September 30, 2024)
• $32.5M — Total Liabilities (As of September 30, 2024)
• $0.775M — Cash from Operations (Nine months ended September 30, 2024)
• $100.0M — Total Equity (As of September 30, 2024)
• $65.2K — Net Cash Used in Investing Activities (Nine months ended September 30, 2024)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Filer of the 10-Q
• September 30, 2024 (date) — End of reporting period
• $42.2 million (dollar_amount) — Total assets
• $32.5 million (dollar_amount) — Total liabilities
• $0.775 million (dollar_amount) — Cash provided by operating activities

FAQ

Filing Documents

• urgn20240930c_10q.htm (10-Q) — 1781KB
• ex_718343.htm (EX-10.1) — 328KB
• ex_718344.htm (EX-31.1) — 17KB
• ex_718345.htm (EX-31.2) — 17KB
• ex_718346.htm (EX-32.1) — 6KB
• ex_718347.htm (EX-32.2) — 6KB
• 0001437749-24-033454.txt ( ) — 7518KB
• urgn-20240930.xsd (EX-101.SCH) — 69KB
• urgn-20240930_cal.xml (EX-101.CAL) — 46KB
• urgn-20240930_def.xml (EX-101.DEF) — 391KB
• urgn-20240930_lab.xml (EX-101.LAB) — 340KB
• urgn-20240930_pre.xml (EX-101.PRE) — 428KB
• urgn20240930c_10q_htm.xml (XML) — 1005KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders ' Equity (Deficit ) 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II. OTHER INFORMATION 36 Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 81 Item 3. Defaults Upon Senior Securities 81 Item 4. Mine Safety Disclosures 81 Item 5. Other Information 81 Item 6. Exhibits 82

Signatures

Signatures 83 Trademarks and Trade Names Unless the context requires otherwise, references in this Quarterly Report to the "Company," "UroGen," "we," "us" and "our" refer to UroGen Pharma Ltd. and its subsidiary, UroGen Pharma, Inc. UroGen , RTGel , and Jelmyto are trademarks of ours that we use in this Quarterly Report. This Quarterly Report also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Quarterly Report appear without the or symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. i Table of Contents

— Financial Information

Part I — Financial Information

Financial Statements

Item 1. Financial Statements. UroGen Pharma Ltd. Condensed Consolidated Balance Sheets (unaudited; in thousands, except share amounts and par value) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 124,916 $ 95,002 Marketable securities 124,659 41,966 Restricted cash 1,073 821 Accounts receivable, net 22,802 15,443 Inventories 7,594 5,673 Prepaid expenses and other current assets 14,053 10,281 Total current assets 295,097 169,186 Non-current assets: Property and equipment, net 608 689 Restricted deposit 175 225 Right of use assets 1,052 1,671 Marketable securities 4,641 4,502 Other non-current assets 370 2,038 Total Assets $ 301,943 $ 178,311 Liabilities and Shareholders' Equity (Deficit) Current liabilities: Accounts payable and accrued expenses $ 19,685 $ 16,538 Employee related accrued expenses 9,029 10,814 Other current liabilities 4,073 3,860 Total current liabilities: 32,787 31,212 Non-current liabilities: Prepaid forward obligation 118,526 109,722 Long-term debt 121,709 98,551 Long-term lease liabilities 212 844 Uncertain tax positions liability 3,194 3,194 Total Liabilities 276,428 243,523 Commitments and Contingencies (Note 18) Shareholders' Equity (Deficit): Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 42,190,815 and 32,490,119 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 115 89 Additional paid-in capital 793,874 614,035 Accumulated deficit ( 768,710 ) ( 679,348 ) Accumulated other comprehensive income 236 12 Total Shareholders' Equity (Deficit) 25,515 ( 65,212 ) Total Liabilities and Shareholders' Equity (Deficit) $ 301,943 $ 178,311 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents UroGen Pharma Ltd. Condensed Consolidated Sta